Hospital Clínic de Barcelona and Vall d'Hebron University Hospital
Barcelona, 08035, Spain
Location contact
Carla Torrent, PhD
CONTACT
Carla Torrent, PhD
PRINCIPAL_INVESTIGATOR
Silvia Amoretti, PhD
CONTACT
Silvia Amoretti, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07039903
Cognitive dysfunctions are present in Bipolar Disorder (BD) and Attention Deficit Hyperactivity Disorder (ADHD) and may negatively impact psychosocial functioning. Further, comorbid BD and ADHD (BD-ADHD) is prevalent, associated with an earlier BD onset and a less favorable prognosis. Nevertheless, there is a paucity of research dedicated to the characterization and treatment of comorbid BD-ADHD.
This study aims to develop and evaluate the effectiveness of a novel psychological group intervention (VECTOR) for adults with BD-ADHD. VECTOR integrates elements from Cognitive Behavioral Therapy (CBT) for ADHD and Functional Remediation (FR) for BD.
Eighty patients will be randomized (1:1) to receive either the VECTOR program (12 weekly group sessions) or treatment as usual (TAU).
It is expected that the VECTOR program will result in greater improvements in functioning and symptom reduction compared to TAU.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Barcelona, 08035, Spain
Carla Torrent, PhD
CONTACT
Carla Torrent, PhD
PRINCIPAL_INVESTIGATOR
Silvia Amoretti, PhD
CONTACT
Silvia Amoretti, PhD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
VECTOR will provide a newly designed intervention, based on the adaptation of two existing evidence-based and effective interventions (CBT for ADHD and FR for BD)(Corrales et al., 2024; Torrent et al., 2013).
Time frame: Baseline, post-treatment (12 weeks) and 12 months
24-item scale assessing disability in six functional domains: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time. Assessed by a blind expert rater.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Severity scale measuring global symptom severity. Assessed by a blind expert rater.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
The ADHD-RS is an 18-items scale self-report version for assessing symptoms for ADHD DSM-IV. It consists of a subscale of inattention (IN, 9-items), another of hyperactivity/impulsivity (H / I, 9-items) and the total (TOT, 18-items). The interviewees are asked about the frequency of the symptoms over the past 6 months.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Assessed by Connors' Adult ADHD Rating Scales Self-report form (CAARS-S:L), a self-report questionnaire evaluating the severity of ADHD symptoms across multiple domains, including inattention and hyperactivity/impulsivity.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Assessed by Connors' Adult ADHD Rating Scales Observer form (CAARS-O-L), an observer-rated questionnaire assessing ADHD symptom severity based on third-party observation, covering the same symptom domains as the self-report version.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Each item is rated on either a 3-point or 5-point Likert-type scale, depending on the symptom being assessed, with higher scores indicating greater severity of depression. The total score for the HDRS-17 ranges from 0 to 52. Common domains evaluated include mood, guilt, suicide ideation, insomnia, anxiety, psychomotor changes, and somatic symptoms.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
11-item clinician-rated scale used to assess manic symptoms such as elevated mood, increased motor activity, sleep disturbance, irritability, and thought disorder. Higher scores reflect more severe manic symptoms. Assessed by a blind expert rater.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
TMT-A assesses processing speed and visual attention. Participants are asked to connect numbered circles in sequence as quickly as possible. Completion time is the outcome measure; shorter times indicate better performance.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
TMT-B assesses cognitive flexibility, task-switching, and executive control. Participants alternate between numbers and letters in sequence (e.g., 1-A-2-B...). Completion time is recorded, with shorter times indicating better performance.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
The CPT is a computerized test that measures sustained attention and impulsivity by recording responses to a series of visual stimuli. Key outcomes include omission errors, commission errors, and reaction time variability.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
The WCST measures cognitive flexibility and executive functioning. Participants must match cards according to varying rules. Key outcomes include number of categories completed and perseverative errors.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
The Stroop Color-Word Test evaluates selective attention and inhibitory control by measuring the ability to name the color of the ink rather than reading the printed word. Interference score is commonly used.
Time frame: Baseline, post-treatment (12 weeks) and 12 months
The Verbal Fluency Test assesses executive control and language by requiring the participant to generate as many words as possible starting with a letter (phonemic) or within a category (semantic) in a limited time.
Time frame: 12 weeks (post)
Client Satisfaction Questionnaire-8 (self-report) - in order to evaluate the treatment satisfaction
Time frame: 12 weeks (post)
The Working Alliance Inventory (WAI) is a self-report questionnaire designed to assess the quality of the therapeutic relationship. It evaluates three key components: agreement on therapeutic goals, agreement on tasks, and the emotional bond between therapist and patient. Higher scores indicate a stronger working alliance.
Hospital Universitari Vall d'Hebron Research Institute
Other
Bridging the Gap in the Study of Bipolar Disorder and Attention Deficit Hyperactivity Disorder: Impact of cognitiVE Reserve and funCtioning in a Newly Designed Treatment intervenTion for comORbidity (VECTOR)
Acronym: VECTOR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06115200
ADHD, Anxiety Disorders
View Trial DetailsNCT07389473
ADHD, Anxiety Disorder Generalized
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05157386
ADHD, Anxiety
Stockholm, Stockholm County, Sweden
View Trial DetailsNCT00181987
ADHD, Attention Deficit Disorder with Hyperactivity
Cambridge, Massachusetts, United States
View Trial Details